FAU Nursing Faculty Member Receives NIH K01 Grant for Breast Cancer Research

Tarsha Jones, Ph.D., principal investigator and an assistant professor of nursing at FAU’s Christine E. Lynn College of Nursing, has received the National Institute of Health (NIH) K01 Career Development Award, a five-year, $772,525 award for a project titled, “Decision Support for Multigene Panel Testing and Family Risk Communication among Racially/Ethnically Diverse Young Breast Cancer Survivors.”

Fred Hutchinson Cancer Research Center, Seatle Children’s and UW Medicine Lay Groundwork for Historic Cancer Partnership

SEATTLE — July 13, 2021 — Fred Hutchinson Cancer Research Center, UW Medicine, Seattle Cancer Care Alliance and Seattle Children’s today announced plans to explore restructuring their longtime relationship to accelerate a d mission of advancing diagnosis, treatment and pioneering of cures for cancer and other diseases.If finalized and approved, the proposed restructure would establish an adult-focused oncology program and, separately, a pediatric oncology program.

Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

Blood cancer patients with COVID-19 fare better with convalescent plasma

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma — the pale yellow liquid in blood that is rich in antibodies — from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection.

Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer

A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).

Researchers Identify New Role for Immune-Boosting Protein “STING” in Treatment of Head and Neck Cancer

In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.

Researchers Discover Common Mechanism Causing Autoimmune Disease and Blood Cancers

In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).

Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting

Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.

CAP Opens PD-L1 Lung Tumor Testing Guideline for Public Comment

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

Yale Researchers Identify Tumor Reactive Immune-Cells to help fight against Advanced Melanoma

According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.

Maryam Lustberg Named Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).

Mount Sinai Health System Launches Center for Light and Health Research

The clinical research conducted through the Center will investigate how to use light to improve people’s lives by stabilizing their circadian rhythms, the natural internal clock that regulates the body’s sleep-wake cycle. Researchers will study how light, either from daylight or electric indoor light, affects circadian rhythms in various populations, from the very young to the very old, including patients with COVID-19, cancer, Alzheimer’s disease, depression, and other illnesses. The goal is to help abate symptoms and improve their sleep, mental health, and cognition.

Researchers Discover Mechanism to Overcome Drug-Resistance in B-Cell Acute Lymphoblastic Leukemia

In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences.

Dr. Rachel Greenup Appointed Chief of Breast Surgical Oncology at Yale

Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.

Strange colon discovery explains racial disparities in colorectal cancer

The colons of African-Americans and people of European descent age differently, new research reveals, helping explain racial disparities in colorectal cancer – the cancer that killed beloved “Black Panther” star Chadwick Boseman.

Dynamic, personalized treatment approach may improve outcomes in gastroesophageal cancers

A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.

Personalizing Cancer Care with Improved Tumor Models

While decades of research have resulted in substantial improvements in surviving cancer, a key challenge remains in identifying new drugs that improve outcomes for patients. In APL Bioengineering, researchers suggest a major hurdle is the paucity of models for cancer research that accurately represent patient tumors. They provide a perspective on strategies using models from individual patients and where the field needs to go in terms of research in animal systems and in culture systems.

Yale study leads to FDA approval of drug to treat non-small cell lung cancer

Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.

Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award

Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.

Henry Ford Cancer Institute and United Outstanding Physicians Partner to Enhance Care, Experience for Cancer Patients

Henry Ford Cancer Institute and United Outstanding Physicians (UOP), a physician organization comprising nearly 1,000 independent private practice physicians across Southeast Michigan, have come together to enhance cancer care and make navigating the cancer journey easier for their patients.

Rutgers Researcher Receives $400K Grant to Reduce Racial Health Disparities in Cancer Care

Anita Kinney, professor at the Rutgers School of Public Health and associate director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is one of ten recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to support investigation into reducing racial health disparities in cancer care through precision oncology and immunotherapy.

First Report Card on Biosimilars in Oncology

SUMMARY Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University…

Yale Cancer Center Study Shows Regional Variation in Genomic Testing for Men with Prostate Cancer

In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.

University of Utah to speed process of bringing new therapeutics to patients

The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.

Four MSK Researchers Receive 2020 Outstanding Investigator Award from the National Cancer Institute

Four MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.

Ingo Mellinghoff Named Chair of MSK’s Department of Neurology

Neuro-oncologist and renowned physician-scientist Ingo Mellinghoff will lead MSK’s distinguished Department of Neurology after previously serving as Acting Co-Chair.

Accelerating Access to Breakthrough Cancer Therapies Leads Morristown Medical Center to Expand Infusion Center

Atlantic Health System has announced the opening of Morristown Medical Center’s new state-of-the-art, patient-centered Infusion Center located in the Carol G. Simon Cancer Center. The first of three phases of expansion of New Jersey’s pre-eminent cancer center, the new unit was funded in large part by donations made by community members in support of the Foundation for Morristown Medical Center’s Growing Forward Campaign.